Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7123520 in rheumatoid arthritis
NCT03001219Phase 2Terminated
- Sponsor
- Roche
- Start
- Dec 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of RO7123520 in rheumatoid arthritis (RA) (4 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Adverse Events at 2 years, Proportion of Participants Achieving an American College of Rheumatology (ACR) 50 Response at Week 12 and 2 more. Started Dec 2016; status: terminated.
02
Drugs
RO7123520
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03001219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03001219.